Skip to main content
. 2018 Apr 18;7(8):e1450710. doi: 10.1080/2162402X.2018.1450710

Table 3.

Patient Incidence of adverse events.

  All Patients (N = 65)
  AEs Any Grade Treatment-related AEs Grade ≥3 AEs Serious
AEs Occurring in >5% of Patients, n (%)      
Diarrhea 30 (46) 11 (17) 8 (12)
Pyrexia 28 (43) 0 (0) 1 (2)
Peripheral edema 26 (40) 0 (0) 0 (0)
Nausea 25 (39) 1(2) 3 (5)
Vomiting 22 (34) 1 (2) 2 (3)
Abdominal pain 21 (32) 3 (5) 4 (6)
Fatigue 19 (29) 3 (5) 1 (2)
Dysgeusia 15 (23) 1 (2) 0 (0)
Cough 11 (17) 0 (0) 0 (0)
Insomnia 11 (17) 1 (2) 0 (0)
Anorexia 10 (15) 1 (2) 0 (0)
Dyspnea 10 (15) 0 (0) 2 (3)
Flatulence 8 (12) 0 (0) 0 (0)
Headache 8 (12) 0 (0) 0 (0)
Infection 8 (12) 1 (2) 4 (6)
Sleep disorder 8 (12) 0 (0) 0 (0)
General physical health deterioration 7 (11) 0 (0) 2 (3)
Upper abdominal pain 7 (11) 0 (0) 0 (0)
Hypertension 7 (11) 1 (2) 0 (0)
Constipation 6 (9) 0 (0) 0 (0)
Nasopharyngitis 6 (9) 0 (0) 0 (0)
Weight decreased 6 (9) 2 (3) 0 (0)
Candidiasis 5 (8) 0 (0) 0 (0)
Dyspepsia 5 (8) 0 (0) 0 (0)
Jaundice 5 (8) 1 (2) 0 (0)
Overdose 5 (8) 2 (3) 5 (8)
Ascites 4 (6) 1 (2) 0 (0)
Back pain 4 (6) 0 (0) 0 (0)
Device related infection 4 (6) 0 (0) 3 (5)
Dizziness 4 (6) 0 (0) 0 (0)
Dry skin 4 (6) 0 (0) 0 (0)
Nocturia 4 (6) 0 (0) 0 (0)
Urinary tract infection 4 (6) 0 (0) 1 (2)

Abbreviations: AE, adverse event.